We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+18.79%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$776M
AUM Growth
+$70.2M
Cap. Flow
+$109M
Cap. Flow %
14.05%
Top 10 Hldgs %
67%
Holding
41
New
7
Increased
5
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$27.8M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$27.7M
3
LITS
Lite Strategy Inc
LITS
+$20.2M
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$12.3M
5
ZYME icon
Zymeworks
ZYME
+$9.61M

Top Sells

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$9.77M
2
RNAC icon
Cartesian Therapeutics
RNAC
+$4M
3
RGNX icon
Regenxbio
RGNX
+$3.92M
4
ZLAB icon
Zai Lab
ZLAB
+$1.14M
5
APLS
Apellis Pharmaceuticals
APLS
+$30.7K

Sector Composition

Rank Sector Weight
1 Healthcare 97.57%
2 Materials 2.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$144M 18.57%
2,166,832
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$81M 10.44%
2,049,545
– –
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
$68.9M 8.88%
10,454,545
+7,121,212
+214% +$27.8M
CDXS icon
4
Codexis
CDXS
$136M
$44M 5.67%
3,054,825
– –
ACRS icon
5
Aclaris Therapeutics
ACRS
$744M
$32.9M 4.24%
1,647,214
– –
VYNE icon
6
VYNE Therapeutics
VYNE
$19.1M
$32.6M 4.2%
1,114
– –
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
$32M 4.13%
1,456,499
-1,335
-0.1% -$30.7K
TCDA
8
DELISTED
Tricida, Inc. Common Stock
TCDA
$29.7M 3.82%
+991,711
New +$27.7M
QTTB icon
9
Q32 Bio
QTTB
$467M
$28.8M 3.71%
78,319
+13,889
+22% +$4.97M
LITS
10
Lite Strategy Inc
LITS
$33M
$26M 3.35%
+330,033
New +$20.2M
ARWR icon
11
Arrowhead Research
ARWR
$12.1B
$25.8M 3.33%
1,900,000
– –
EIGR
12
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$21.9M 2.82%
59,709
– –
AMRS
13
DELISTED
Amyris Inc.
AMRS
$18.1M 2.33%
2,826,711
– –
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.4B
$17.4M 2.24%
62,220
+35,000
+129% +$6.15M
KALA icon
15
KALA BIO
KALA
$12.3M
$14.3M 1.85%
418
– –
NBRV
16
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$14.2M 1.83%
16,297
– –
OBSV
17
DELISTED
ObsEva SA Ordinary Shares
OBSV
$14M 1.8%
+925,000
New +$12.3M
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
$12.2M 1.57%
906,000
+106,000
+13% +$1.33M
SBBP
19
DELISTED
Strongbridge Biopharma plc.
SBBP
$11.5M 1.48%
1,918,132
– –
RNAC icon
20
Cartesian Therapeutics
RNAC
$225M
$10.3M 1.33%
26,020
-11,286
-30% -$4M
SLNO
21
DELISTED
Soleno Therapeutics
SLNO
$10.2M 1.31%
290,646
+21,744
+8% +$638K
DCPH
22
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$9.95M 1.28%
+252,942
New +$7.45M
GLMD icon
23
Galmed Pharmaceuticals
GLMD
$4.1M
$9.43M 1.22%
+4,404
New +$6.38M
ZYME icon
24
Zymeworks
ZYME
$1.66B
$9.17M 1.18%
+620,134
New +$9.61M
SRRA
25
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$7.22M 0.93%
60,957
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Vivo Capital held 41 positions worth $776M, up 9.9% from $706M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Vivo Capital deployed $109M of net new capital in Q2 2018, opening 7 new positions and adding to 5 existing holdings. Its largest new stake was Tricida, Inc. Common Stock: 991,711 shares worth $29.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Cartesian Therapeutics, an estimated $4M trimmed.

  • Vivo Capital's largest Q2 2018 buy was Tricida, Inc. Common Stock: 991,711 shares worth $29.7M.
  • Vivo Capital added most to Kadmon Holdings, Inc. in Q2 2018, an estimated $27.8M increase.
  • Vivo Capital's biggest Q2 2018 reduction was Cartesian Therapeutics, cutting an estimated $4M.
  • Vivo Capital fully exited Aimmune Therapeutics in Q2 2018, selling an estimated $9.77M.
  • Vivo Capital's ten largest holdings make up 67% of its $776M portfolio in Q2 2018.
  • Vivo Capital opened 7 new positions and closed 1 in Q2 2018.
  • Vivo Capital's portfolio value rose 9.9% quarter-over-quarter to $776M.

Based on Vivo Capital's 13F filing for Q2 2018, filed 10 Aug 2018.